| Neo IRENIE (NEOadjuvant Ipilimumab, RElatlimab, NIvolumab Evaluation) (NCT06999980) | Melanoma Institute Australia | 2026-02-09 |
| The Multicentre Selective Lymphadenectomy Trial - 3 (NCT07049276) | Melanoma Institute Australia | 2025-10-01 |
| Stereotactic Ablative Radiotherapy (XRT) and Immunotherapy for Oligometastatic Extracranial Melanoma (NCT06767306) | Melanoma Institute Australia | 2025-03-06 |
| Neoadjuvant Nivolumab and Relatlimab in Cutaneous Squamous Cell Carcinoma (NCT06288191) | Melanoma Institute Australia | 2024-06-21 |
| Neoadjuvant Nivolumab and Relatlimab in Merkel Cell Carcinoma (NCT06151236) | Melanoma Institute Australia | 2024-03-11 |
| Neoadjuvant Pembrolizumab and Lenvatinib for Mucosal Melanoma (NCT05545969) | Melanoma Institute Australia | 2024-03-01 |
| A Phase 2 Clinical Trial of Neoadjuvant Relatlimab and Nivolumab in High Risk, Clinical Stage II Cutaneous Melanoma (NCT05418972) | Melanoma Institute Australia | 2023-08-14 |
| Molecular Profiling and Matched Targeted Therapy for Patients With Unresectable Advanced or Metastatic Melanoma (NCT02645149) | Melanoma Institute Australia | 2021-11-22 |
| Personalised Immunotherapy Platform (NCT06536257) | Melanoma Institute Australia | 2021-06-08 |
| A Phase II Study of Neoadjuvant Pembrolizumab & Lenvatinib for Resectable Stage III Melanoma (NCT04207086) | Melanoma Institute Australia | 2020-11-11 |
| Intralesional Sclerosant for in Transit and Cutaneous Melanoma Metastases (NCT03754140) | Melanoma Institute Australia | 2020-05-20 |
| Anti-PD 1 Brain Collaboration + Radiotherapy Extension (ABC-X Study) (NCT03340129) | Melanoma Institute Australia | 2019-08-14 |
| A Study to Evaluate Neoadjuvant Sonidegib Followed by Surgery or Imiquimod in the Management of Basal Cell Carcinoma (NCT03534947) | Melanoma Institute Australia | 2019-07-23 |